Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
Alaunos Therapeutics (TCRT) will announce its financial results for Q3 2022 on November 14, 2022, prior to U.S. market opening. Following this, a conference call will be held at 8:30 a.m. ET to discuss the results and provide a corporate update. The company specializes in oncology-focused cell therapies, utilizing its proprietary Sleeping Beauty gene transfer technology to develop T-cell receptor therapies targeting oncogenic gene mutations like KRAS, TP53, and EGFR.
- The upcoming financial results may provide insights into the company's growth strategy and performance.
- None.
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.
Register for the live webcast using the link here or by visiting the “Investors” section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. After the live webcast, the event will be archived on the Company’s website for approximately 30 days after the call.
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has a clinical and strategic collaboration with the National Cancer Institute. For more information, please visit www.alaunos.com.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
FAQ
When will Alaunos Therapeutics report its Q3 2022 financial results?
What time is the conference call for Alaunos Therapeutics Q3 results?
What is the focus of Alaunos Therapeutics?
